



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

**CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)**

Baseline Patient Demographic

To be completed by the ordering provider.

Diagnosis: _____ Height: _____ cm Weight: _____ kg Body Surface Area: _____ (m²)
 NKDA - No Known Drug Allergies Allergies: _____
Therapy Plan orders extend over time (several visits) including recurring treatment.

Please specify the following regarding the entire course of therapy:

Duration of treatment: _____ weeks _____ months _____ unknown

Treatment should begin: as soon as possible (within a week) within the month****Plans must be reviewed / re-ordered at least annually. ******ORDERS TO BE COMPLETED FOR EACH THERAPY****ADMIT ORDERS** Height and weight Vital signs**HYPOTENSION DEFINED ADMIT** Nursing communication

Prior to starting infusion, please determine the patient's threshold for hypotension as defined by the following parameters. This information will be needed in the event of an infusion reaction.

Hypotension is defined as follows:

1 month to 1 year - systolic blood pressure (SBP) less than 70

1 year to 11 years - systolic blood pressure (SBP) less than 70 + (2 x age in years)

11 years to 17 years - systolic blood pressure (SBP) less than 90

OR any age - systolic blood pressure (SBP) drop of more than 30% from baseline.

Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.

PREGNANCY TESTS AT DALLAS AND PLANO**Nursing communication**

Only one pregnancy test is necessary, based on facility capabilities. Please utilize the lab that is available per facility.

 Patient requires a pregnancy test (based on organizational policy, female patients 10 years of age or over require a pregnancy test)**Pregnancy test, urine - POC**STAT, ONE TIME, for females \geq 10 years old. If positive, do NOT infuse and contact the ordering provider.**Gonadotropin chorionic (HCG) urine**STAT, ONE TIME, unit collect, for females \geq 10 years old. If positive, do NOT infuse and contact ordering provider.**NURSING ORDERS**

Please select all appropriate therapy

IV START NURSING ORDERS Insert peripheral IV / Access IVAD

Place PIV if needed or access IVAD if available

 lidocaine 1% BUFFERED (J-TIP LIDOCAINE)

0.2 mL, INTRADERMAL, PRN

 when immediate procedure needed when procedure will take about 1 minute patient / family preference for procedureAdministration Instructions: NOTE: Do not use this medication in patients with bleeding disorders, platelets \leq 20,000, or in patients taking anticoagulants, when accessing implanted ports or using a vein that will be utilized for chemotherapy administration, nor for pre-term infants or neonates.



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

**CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)**

ORDERS TO BE COMPLETED FOR EACH THERAPY

NURSING ORDERS, CONTINUED

Please select all appropriate therapy

lidocaine - prilocaine (EMLA) cream

TOPICAL, PRN

when more than 60 minutes are available before procedure when procedure will take more than 1 hour

patient / family preference for procedure

Administration Instructions: NOTE: In children < 3 months of age, or < 5 kg in weight, maximum application time is 1 hour.

lidocaine - tetracaine (SYNERA) patch

TOPICAL, PRN

when 20 - 30 minutes are available before procedure when procedure will take more than 1 hour

when anticipated pain is less than 5 mm from skin surface patient / family preference for procedure

lidocaine with transparent dressing 4% kit

TOPICAL, PRN

when 20 - 30 minutes are available before procedure when procedure will take more than 1 hour

patient / family preference for procedure

Heparin flush

heparin flush

10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de-accessing the IVAD.

heparin flush

100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de-accessing IVADs.

Sodium chloride flush

Sodium chloride flush 0.9% injection

1 - 20 mL, INTRAVENOUS, PRN, IV line flush

Sodium chloride - preservative free 0.9% injection

1 - 30 mL, INTRAVENOUS, PRN, IV line flush

PRE-MEDICATIONS

Acetaminophen pre-medication 30 minutes prior (15 mg / kg, maximum 650 mg)

Nursing communication

Administer only one of the acetaminophen orders, suspension or tablets, do not give both.

acetaminophen suspension

15 mg / kg, ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

acetaminophen tablet

15 mg / kg ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)

ORDERS TO BE COMPLETED FOR EACH THERAPY

PRE-MEDICATIONS, CONTINUED

Diphenhydramine pre-medication 30 minutes prior (1 mg / kg, maximum 50 mg)

Nursing communication

Administer only one of the diphenhydrAMINE pre-medication orders, liquid, capsule or injection, do not give more than one of the orders as a pre-medication.

diphenhydrAMINE liquid

1 mg / kg, ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

diphenhydrAMINE capsule

1 mg / kg ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

diphenhydrAMINE injection

1 mg / kg, INTRAVENOUS, 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

methylPREDNISolone RTA infusion

1 mg / kg INTRAVENOUS, for 1 dose. Pre-med give 30 minutes prior to infusion. For doses \geq 10 mg / kg, see Policy 7.10.16, assess and document heart rate and blood pressure (BP) every 15 minutes during infusion and for 1 hour after the infusion is complete. Doses > 15 mg / kg should be given over a minimum of 1 hour.

Dose: _____

INTRA-PROCEDURE

Vital signs

Obtain baseline vitals prior to start of inFLIXimab, then monitor vitals every 15 minutes during inFLIXimab infusion and for 30 minutes after infusion completed. In the event of any adverse reaction or other infusion related symptoms, the infusion should be stopped and notify the ordering provider.

Nursing Communcation

Infusion rate initial therapy at 10 mL / hour x 15 minutes. Increase rate to 20 mL / hour x 15 minutes. Increase rate to 40 mL / hour x 15 minutes. Increase rate to 80 mL / hour x 15 minutes. Increase rate to 150 mL / hour x 30 minutes. Increase rate to 250 mL / hour x 30 minutes.

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete

Physician Communcation Order

Recommended inFLIXimab starting dose = 5 mg / kg. Please enter the dose of inFLIXimab in "mg" to facilitate prior authorization requirements. Vial size is 100 mg, if possible and clinically acceptable, round to nearest 100 mg.

Infliximab (REMICADE or biosimilar) - Loading Dose
Select one product below:

inFLIXimab (REMICADE)
in sodium chloride 0.9% 250 mL infusion

INTERVAL: Every 14 days Defer Until: _____ Duration: 2 treatments

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

**CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)**

ORDERS TO BE COMPLETED FOR EACH THERAPY

INTRA-PROCEDURE, CONTINUED

**inFLIXimab-dyyb (INFLECTRA)
in sodium chloride 0.9% 250 mL infusion** **INTERVAL:** Every 14 days **Defer Until:** _____ **Duration:** 2 treatments

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete

**inFLIXimab-abda (RENFLEXIS)
in sodium chloride 0.9% 250 mL infusion** **INTERVAL:** Every 14 days **Defer Until:** _____ **Duration:** 2 treatments

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete

Infliximab (REMICADE or biosimilar) - Maintenance Dose
Select one product below:

**inFLIXimab (REMICADE)
in sodium chloride 0.9% 250 mL infusion** **INTERVAL:** Every 8 weeks **Defer Until:** _____ **Duration:** Until Discontinued

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete

**inFLIXimab-dyyb (INFLECTRA)
in sodium chloride 0.9% 250 mL infusion** **INTERVAL:** Every 8 weeks **Defer Until:** _____ **Duration:** Until Discontinued

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

**CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)**

ORDERS TO BE COMPLETED FOR EACH THERAPY

INTRA-PROCEDURE, CONTINUED

inFLIXimab-abda (RENfLEXIS) **INTERVAL:** Every 8 weeks **Defer Until:** _____ **Duration:** Until Discontinued
in sodium chloride 0.9% 250 mL infusion

INTRAVENOUS, at 125 mL / hour, ONCE, for 1 dose. Administer over 2 hours. Must be administered with a 0.2 micron disk filter.

Dose: _____

	Rate	Time at that rate
Initial Infusion Rate	10 mL / hour	for 15 minutes
Increase Rate to	20 mL / hour	for 15 minutes
Increase Rate to	40 mL / hour	for 15 minutes
Increase Rate to	80 mL / hour	for 15 minutes
Increase Rate to	150 mL / hour	for 30 minutes
Increase Rate to	250 mL / hour	for 30 minutes
Then stop infusion		Infusion complete

Therapy Appointment Request

Please select department for the therapy appointment request:

Expires in 365 days

- Dallas Special Procedures Plano Infusion Center Dallas Allergy Dallas Transplant Dallas Neurology

EMERGENCY MEDICATIONS

Nursing communication

1. Hives or cutaneous reaction only – no other system involvement **PATIENT IS HAVING A DRUG REACTION:**

- a. Stop the infusion
- b. Give diphenhydramine as ordered
- c. Check vitals including blood pressure every 5 minutes until further orders from provider.
- d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one
- e. Notify provider for further orders

2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling **PATIENT IS HAVING ANAPHYLAXIS:**

- a. Stop the infusion
- b. Call code – do not wait to give epinephrine
- c. Give epinephrine as ordered
- d. Notify provider
- e. Check vitals including blood pressure every 5 minutes until the code team arrives.
- f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.
- g. Give diphenhydramine once as needed for hives
- h. May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team arrives.
- i. May give albuterol as ordered for wheezing with oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation.

Hypotension is Defined as Follows:

1 month to 1 year – systolic blood pressure (SBP) less than 70
 1 year to 11 years – systolic blood pressure (SBP) less than 70 + (2 x age in years)
 11 years to 17 years – systolic blood pressure (SBP) less than 90
 OR any age – systolic blood pressure (SBP) drop more than 30% from baseline.
 Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.

**EPINEPHrine Injection Orderable For Therapy Plan
(AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg**

0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses

Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.

Dose: _____



Patient Name: _____

Date of Birth: _____

PHYO
CMC85136-002NS Rev.11/2021

**CHST RITUXIMAB
(INFLIXIMAB or BIOSIMILAR)
INFUSION THERAPY PLAN (DERMATOLOGY)**

ORDERS TO BE COMPLETED FOR EACH THERAPY

EMERGENCY MEDICATIONS, CONTINUED

Cardio / Respiratory Monitoring
Rationale for Monitoring: High risk patient (please specify risk)

- Clinically significant cardiac anomalies or dysrhythmias
- Recent acute life-threatening event
- Unexplained or acutely abnormal vital signs
- Artificial airway (stent, tracheostomy, oral airway)
- Acute, fluctuating or consistent oxygen requirements

Monitor Parameters (select all that apply): Heart rate Oxygen saturation Respiratory rate
Telemetry Required: Yes No

diphenhydrAMINE injection

1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day.

Dose: _____

Albuterol for aerosol

0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose.

Dose: _____

POST - PROCEDURE

Nursing communication

Flush PIV or IVAD with 20 mL 0.9% sodium chloride (250 mL bag) at the completion of the infusion.
Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD.
Discontinue PIV prior to discharge.

Sodium chloride 0.9% infusion

INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose.

Dose: _____

(circle one):
MD DO

Signature of Provider

Credentials

Date

Time

Printed Name of Provider